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ABSTRACT
Aims/Introduction: Monogenic diabetes accounts for approximately 1–2% of all dia-
betes, and is difficult to distinguish from type 1 and type 2 diabetes. Molecular diagnosis
is important, as the molecular subtype directs appropriate treatment. Patients are selected
for testing according to clinical criteria, but up to 80% of monogenic diabetes in the UK
has not been correctly diagnosed. We investigated outcomes of genetic testing in our
center to compare methods of selecting patients, and consider avenues to increase diag-
nostic efficiency.
Materials and Methods: We reviewed 36 probands tested for monogenic diabetes in
the last 10 years in a large adult diabetes outpatient clinic, serving an ethnically diverse
urban population. We compared published clinical criteria and an online maturity onset
diabetes of the young calculator applied to these 36 patients, and presented the predic-
tions together with the molecular results.
Results: The overall mutation detection rate was 42%, reflecting the strict clinical selec-
tion process applied before genetic testing. Both methods had high sensitivity for identify-
ing patients with mutations: 88 and 89% for the clinical criteria and online calculator,
respectively. Cascade testing in a total of 16 relatives led to diagnosis of a further 13
cases.
Conclusions: Existing patient selection criteria were effective in identifying patients
with monogenic forms of diabetes, but the number of patients missed using these strict
criteria is unknown. Because of the potential savings resulting from correct molecular diag-
nosis, it is possible that testing a larger pool of patients using less stringent selection crite-
ria would be cost-effective. Further evidence is required to inform this assessment.
INTRODUCTION
It is known that 1–2% of patients with diabetes have a mono-
genic cause of their disease, which can result from mutations in
a number of different genes. HNF1A and HNF4A mutations
cause autosomal dominant diabetes, which usually occurs in
childhood or early adulthood, and is responsive to treatment
with sulphonylureas1. Mutations in the GCK gene cause autoso-
mal dominant lifelong stable fasting hyperglycemia, which does
not require treatment, as patients do not appear to develop the
complications of diabetes2. HNF1B mutations cause diabetes
with malformations of the kidney and uterus (renal cysts and
diabetes or RCAD syndrome), another dominant condition,
which generally requires treatment with insulin3. The
m.3423A>G mutation in the mitochondrial genome includes
diabetes as one of its many phenotypic consequences; this dia-
betes also requires insulin treatment4.
Despite the treatment implications and potential cost savings
from making these molecular diagnoses, it was estimated in
2010 that 80% of the approximately 26,000 cases in the UK are
currently undiagnosed5. Clinical criteria for selecting patients
for molecular testing have been produced, but these are detailed
and complex because of the heterogeneous nature of mono-
genic forms of diabetes, and the mutation detection rate whenReceived 21 May 2015; revised 3 September 2015; accepted 14 September 2015
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these are applied is unknown6. At present, testing rates vary
across the UK, indicating a lack of standardization of testing
across clinicians and centers5.
An online tool is available at http://www.diabetes-
genes.org/content/mody-probability-calculator, which has been
designed to predict the likelihood of identifying a mutation in
the HNF1A, HNF4A or GCK genes using basic clinical infor-
mation (age at diagnosis, sex, treatment, body mass index, gly-
cated hemoglobin, age and presence or absence of a parent
with diabetes), with 75.5% the highest chance possible using
this algorithm7. Further development of the calculator is ongo-
ing, particularly to include patients from different ethnic back-
grounds, as the data used to train the calculator was from
individuals of white European origin, as this represents the lar-
gest dataset available.
To investigate the effectiveness of published tools for selec-
tion of patients for genetic testing, and the outcomes of this
testing in our large multi-ethnic urban diabetes center, we
reviewed all genetic tests carried out in adults over the past
decade, and present here the results of these tests.
MATERIALS AND METHODS
We ascertained the details of patients referred to the Exeter
Molecular Genetics Laboratory for monogenic diabetes testing
in the 10-year period from 2004 to February 2014. All sam-
ples from the Trust are sent to this laboratory for molecular
testing, so this is a complete list of testing arranged by clini-
cians within the Trust. All of the patients included in the
study attended the diabetes outpatient clinic at Guy’s and St
Thomas’ NHS Foundation Trust on at least one occasion
between 2004 and 2014, having been referred by their general
practitioner. Genetic testing was requested when the clinician’s
index of suspicion for a monogenic form of diabetes was
high.
The pathogenicity of the mutations identiﬁed during genetic
testing was assessed by the Exeter Molecular Genetics Labora-
tory, which is one of the principle centers for molecular diag-
nosis of diabetes worldwide. In-house expertise was combined
with application of the Practice Guidelines for the Evaluation of
Pathogenicity and the Reporting of Sequence Variants in Clini-
cal Molecular Genetics, produced by the United Kingdom
Association for Clinical Genetic Science (which can be viewed
at http://www.acgs.uk.com/committees/quality-committee/best-
practice-guidelines).
Proband diagnostic testing and cascade testing in relatives
were analyzed separately. Paper and electronic records were
reviewed to obtain clinical information for probands, including
date of diagnosis, treatment, body mass index, family history,
biochemical parameters (HbA1c, antibody testing, C-peptide)
and ethnic origin.
The principal criteria given in the 2008 Consensus Criteria
for identiﬁcation of HNF1A and HNF4A monogenic diabetes
were onset of diabetes below age 25 years in one family mem-
ber, presence of diabetes in two consecutive generations,
absence of pancreatic auto-antibodies within 3 years of onset of
diabetes and evidence of continuing endogenous insulin after
3 years of diabetes6. These criteria were assessed in the pro-
bands who had undergone genetic testing. Antibodies tested
included either or both of GAD and ICA. Evidence of ongoing
insulin production included patients not receiving insulin treat-
ment, or patients with C-peptide greater than 200 pmol/L after
3 years on insulin.
Clinical data were also entered into the online maturity onset
diabetes of the young (MODY) calculator for patients diag-
nosed with diabetes below the age of 35 years to generate a
percentage prediction of the chance of detecting a mutation in
HNF1A, HNF4A or GCK; the tool has not been validated for
patients diagnosed after this age.
RESULTS
A total of 79 probands in the study center underwent genetic
testing for genes causing monogenic diabetes between 2004 and
February 2014. Of these, 36 probands were seen in the adult
diabetes clinic, and were tested for one or more of the mono-
genic diabetes genes GCK, HNF1A, HNF4A and HNF1B or the
mitochondrial m.3243A>G mutation. A total of 28 of these
tests (78%) were requested in the last 5 years since 2009. A
total of 15 patients had a molecular diagnosis identiﬁed (42%):
ﬁve HNF1A, ﬁve m.3243A>G, three HNF4A and two GCK.
Clinical characteristics of the probands are given in Table 1.
The remaining 43 probands were tested in a pediatric clinic, a
genetics clinic or a renal clinic; one patient had an HNF1A
mutation, another a KCNJ11 mutation and nine had mutations
in HNF1B. The focus of this study was genetic testing patterns
and outcomes within the adult diabetes center, and the remain-
der of this report therefore focuses on the 36 probands tested
in the adult diabetes clinic.
Of the adult diabetes patients with no molecular diagnosis,
seven had complete testing of HNF1A and HNF4A including
multiplex ligation-dependent probe ampliﬁcation (MLPA) for
deletions and duplications. Nine probands had partial testing of
these genes; these patients were no longer attending the clinic
and it was therefore not possible to complete this testing. Four
of the patients with no molecular diagnosis were only tested for
the mitochondrial mutation, as their phenotype was not
thought to be compatible with HNF1A or HNF4A diabetes.
Most patients were not tested for GCK, as this was only
requested in patients with mildly raised fasting glucose.
Probands were assessed according to the 2008 Consensus cri-
teria for identiﬁcation of patients with HNF1A and HNF4A
mutations6. Evidence was not available to allow assessment of
all four categories in all probands. Three probands met all four
criteria; one of these had an HNF4A mutation. A total of 16
probands met three out of four criteria; four of these had an
HNF1A mutation, two had an HNF4A mutation and one had
the mitochondrial mutation. The remaining 18 probands met
one or two of the criteria based on available information; these
included one patient with an HNF1A mutation, two with GCK
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mutations and four with the mitochondrial mutation (Fig-
ure 1).
Only one tested patient had positive autoantibodies, and this
patient had no mutation detected. Mutations were found in
individuals with negative antibodies at the time of diagnosis
(three mutations in 11 patients tested), in patients with negative
antibodies more than 3 years after diagnosis (eight of 13
patients) and in those without antibody results (four of 11
patients).
Positive C-peptide is used to assess ongoing endogenous
insulin secretion, and is likely to be present in patients with
diabetes caused by HNF1A and HNF4A mutations. Mutations
in these genes were found in six of 21 patients with positive C-
peptide, no patients with low C-peptide, and two of 13 patients
where C-peptide was not measured.
Overall, of the eight patients with mutations in HNF1A and
HNF4A, seven met three of four of the 2008 consensus criteria.
For the ﬁnal patient, insufﬁcient information was available
regarding ages of onset within the family and biochemical test-
ing to assess the patient against these criteria. A total of 12
patients who met three or four of the criteria did not have a
mutation in HNF1A or HNF4A, giving a mutation detection
rate of seven out of 19 (37%) using this tool, with sensitivity
88% and speciﬁcity 57% (Table 2).
All probands were also assessed using the online MODY cal-
culator; the predictions are shown divided by molecular result
in Figure 2. Overall, 31 of 36 patients could be assessed using
the tool, as ﬁve probands were over the age of 35 years at diag-
nosis, which falls outside the range that can be calculated using
this tool. A total of 16 patients were predicted to have a greater
than 20% chance of detecting a mutation; of these, eight had a
mutation detected in HNF1A, HNF4A or GCK (50%). A total
of 15 patients had prediction scores less than 20%, of which
one had a mutation in one of the three genes, giving a sensitiv-
ity of 89% and speciﬁcity 64% using the 20% threshold
(Table 2).
One patient with diabetes diagnosed in early childhood had
a close family history of the m.3243A>G mutation, and there-
fore this patient’s diabetes was assumed to be mitochondrial in
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Figure 1 | Mutation detection according to the 2008 consensus
criteria: in patients meeting three or four or the criteria, seven of 19
(37%) had a mutation in HNF1A or HNF4A, whereas one (5%) had a
mitochondrial mutation. In patients meeting only one or two of the
criteria, one of 17 (5%) had a mutation in HNF1A or HNF4A, whereas six
of 17 (35%) had a mutation in other genes.
Table 2 | Performance of the 2008 Consensus criteria and online
MODY calculator in predicting patients with a mutation in HNF1A or
HNF4A (and GCK for the MODY calculator)
2008 criteria 3/4 criteria met 0–2 criteria met
Mutation 7 1 Sensitivity 88%
No mutation 12 16 Specificity 57%
PPV 37% NPV 94%
MODY calculator Predicted >20% Predicted <20%
Mutation 8 1 Sensitivity 89%
No mutation 8 14 Specificity 64%
PPV 50% NPV 93%
MODY, maturity onset diabetes of the young; NPV, negative predictive
value; PPV, positive predictive value.
Table 1 | Clinical characteristics of probands who underwent genetic testing
Sex Ethnicity Median age
at testing,
years (range)
Median years from
diagnosis to test
(range)
Average age
of onset
(years)
Average
BMI
Delayed/no
insulin
requirement (%)M F White
European
Afro-
Caribbean
Other
HNF1A/HNF4A 2 6 6 0 2 34 (18–51) 17 (0–31) 20.0 26.6 88
GCK 2 0 2 0 0 35 (32–37) 0 34.5 25.7 100
m.3243A>G 1 4 2 3 0 44 (31–53) 21 (0–25) 27.2 22.8 20
No mutation 13 8 14 1 6 36 (15–68) 12 (0–53) 23.7 27.7 62
All patients 18 18 24 4 8 35 (15–68) 15 (0–53) 24.0 26.7 72
Patient numbers are too small to draw formal statistical conclusions regarding the association between these clinical characteristics and the pres-
ence or absence of the different types of mutation. However, it is notable that the patients with mitochondrial diabetes tended to require insulin
earlier than those with HNF1A and HNF4A diabetes, which is consistent with results from larger cohorts of patients4. All 36 patients had at least one
close family member with diabetes.
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origin, despite the test in blood failing to show the mutation.
This illustrates the importance of testing multiple tissues, and
considering family history and phenotype when diagnosing
mitochondrial diabetes, as the mutation might not be present
in the blood, particularly in adults.
Cascade testing was carried out in 16 individuals from ﬁve
families (Table 3). All 11 relatives with diabetes who underwent
testing carried the familial mutation, as expected. Of the ﬁve
relatives without diabetes who underwent predictive testing,
three did not carry the familial mutation, releasing these indi-
viduals and their offspring from the necessity for ongoing
surveillance for diabetes.
Of the eight probands and ﬁve relatives with diabetes seen in
our center diagnosed with HNF1A or HNF4A diabetes, three
were prescribed a sulphonylurea drug at the time of molecular
testing. At the most recent review, ten patients were prescribed
a sulphonylurea; of the remaining three patients, one declined a
trial of oral medication, and two were treated with diet only.
Eight of the ten patients on a sulphonylurea required insulin
treatment in addition to oral hypoglycaemic agents. Four
patients were pregnant or attempting to conceive at the time of
diagnosis or follow up, and their management was therefore
altered accordingly.
DISCUSSION
Monogenic diabetes is an underdiagnosed condition with signif-
icant implications for patient management. We have presented
our experience of selecting patients for genetic testing over the
past decade. A total of 28 patients from 15 families received a
molecular diagnosis during this time. These diagnoses allowed
patients to understand their chance of passing on their condi-
tion to their children, assisted with cascade testing in other
family members and affected clinical management of diabetes.
This was particularly relevant in female patients of childbearing
age, as an awareness of the diagnosis allowed speciﬁc manage-
ment of maternal diabetes as well as preparation for the possi-
bility of neonatal complications.
Nine patients who were suspected to have HNF1A or
HNF4A mutations did not receive full sequencing and dosage
analysis by MLPA for both genes. Before April 2013, the
diagnostic laboratory used a staged testing process with differ-
ent levels of testing attracting different costs. The levels
include testing a single common mutation in HNF1A,
sequencing of one or both genes, and MLPA testing for dele-
tions and duplications within both genes. The report format
included this information, but in some cases the headline of
the report stating that no mutation had been found appears
to have been interpreted to mean that complete testing had
been carried out, when not all levels of testing had been com-
pleted, despite a high predicted chance of ﬁnding a mutation.
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Figure 2 | Results from the maturity onset diabetes of the young probability calculator divided by molecular diagnosis: green bar, GCK; purple bar,
HNF1A; pink bar, HNF4A; yellow bar, m.3243A>G; blue bar, no mutation identified. The calculator has been trained to detect individuals with GCK,
HNF1A and HNF4A mutations; patients with mitochondrial diabetes are shown here for purposes of comparison along with the patients in whom
no mutation was identified.
Table 3 | Cascade tests carried out in 16 members of five families
Family Gene Relatives with
diabetes
Relatives without
diabetes
1 m.3243A>G 1 (1 pos) 0
2 HNF1A 3 (3 pos) 1 (1 pos)
3 HNF4A 4 (4 pos) 2 (1 pos)
4 HNF4A 1 (1 pos) 0
5 HNF4A 2 (2 pos) 2 (0 pos)
Total 11 (11 pos) 5 (2 pos)
The total number of tests is shown for relatives with diabetes (diagnos-
tic cascade testing) and relatives without diabetes (predictive cascade
testing), including the number of positive tests in brackets (pos).
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This illustrates the complexity of arranging and interpreting
genetic testing, where the residual chance of a false negative
result might be difﬁcult to appreciate. The testing process is
now much simpler, so the results issued since April 2013 are
easier to interpret.
Mutation detection rates have been reported to vary between
different populations, with higher pick-up rates in European
studies, and lower rates in South and East Asian studies8,9. Very
few studies of Afro-Caribbean populations have been published.
Our center caters for a population of high ethnic variability,
which is reﬂected in the patients reported here. In this cohort,
mutations were identiﬁed in patients from a wide variety of
ethnic backgrounds; larger numbers would be required to detect
an effect of ethnicity on mutation rate.
Cascade testing only occurred within the UK in ﬁve of the
15 families in whom a proband received a molecular diagnosis.
In part, this reﬂects the nature of the urban population, with
many patients having no relatives within our area, or even in
the UK. However, it must be noted that the resources of time
and expertise required for cascade testing in terms of contacting
families, and arranging appropriate referrals and testing are not
readily available in busy mainstream diabetes outpatient clinics.
This situation is addressed in our center by the dedicated
Monogenic Diabetes clinic, with input from specialists in dia-
betes and clinical genetics, and specialist diabetes nurses.
Diabetes caused by HNF1A and HNF4A mutations is classi-
cally responsive to sulphonylurea treatment. In this patient
cohort, patients were appropriately offered sulphonylurea treat-
ment after molecular diagnosis, but most patients still required
insulin in addition to oral hypoglycemic agents. This is likely to
reﬂect several factors: ﬁrst, four of the 13 patients were pregnant
or attempting to conceive, which affected the management
options available; second, molecular diagnoses in this cohort in
many cases followed many years after onset of diabetes, and in
the longer term many HNF1A and HNF4A patients do progress
to requiring insulin; and third, intensive education and support is
required to transfer patients off insulin, and this is complicated
by higher rates of patient mobility, language barriers and low
socioeconomic status in urban diabetes centers. Collection of
real-world data regarding treatment alteration after molecular
diagnosis will be required to inform health economic assessment
of the cost-effectiveness of genetic testing in diabetes.
The characteristics of tested probands were assessed using
the 2008 consensus criteria (which are directed at identifying
HNF1A and HNF4A mutation patients) and the online MODY
calculator (trained to identify patients with HNF1A, HNF4A
and GCK mutations)6,7. Patients with mitochondrial and
HNF1B diabetes can be more readily detected through their
clinical and biochemical features. A comparison of the perfor-
mance of the two tools is given in Table 2, showing that both
tools give good discrimination between patients with and with-
out mutations. However, it is not known what proportion of
individuals with diabetes would need to be tested if these crite-
ria were widely applied, and therefore whether the cost associ-
ated with these thresholds would be manageable within NHS
budgets.
Using the online MODY calculator, eight of nine patients
with HNF1A, HNF4A or GCK mutations scored over 20%. The
patient with an HNF1A mutation with a score of 2.6% on the
calculator would have scored 75.5% if she had not been treated
with insulin within 6 months of diagnosis. This patient was
diagnosed in her teens in the early 1990s, when all slim adoles-
cent patients with diabetes would have been assumed to have
type 1 diabetes and automatically treated with insulin. This
illustrates the need for caution when using the MODY calcula-
tor for patients who were diagnosed before awareness of mono-
genic diabetes was widespread, as the calculator is very sensitive
to the timing of insulin treatment. Of the four individuals with
prediction scores of 75.5% in whom no mutations were identi-
ﬁed, two had complete testing of HNF1A and HNF4A includ-
ing MLPA, whereas two did not.
Our experience (albeit with small patient numbers) suggests
that a high score using available tools does yield a high muta-
tion detection rate (42% overall in this cohort). However, expe-
rience in other monogenic subsets of complex diseases (e.g.,
familial hypercholesterolemia, breast cancer) has shown that the
higher the speciﬁcity of the test the lower the sensitivity. This
means that using these strict criteria is likely to miss a propor-
tion of affected patients. A limitation of the present study was
that standardized criteria were not in use in this clinic during
this period to identify patients suitable for genetic testing. This
means that the total number of patients seen in the clinic who
would have met these testing criteria is unknown. This is being
addressed prospectively by the implementation of standardized
testing criteria.
At present, there are no health economic assessments based
on real-world evidence to determine how stringent the criteria
should be to maximize the cost-effectiveness of the testing, but
given the potential cost savings of making these diagnoses and
tailoring treatment for all family members, it is possible that
testing more widely would be cost-effective overall. Applying
less stringent criteria, testing larger numbers of patients and
reducing the mutation detection rate is the only method to dis-
cover how many patients are missed by applying these strict
criteria. With the costs of genetic testing falling, and the contin-
uing drive to increase awareness of monogenic diabetes, this
increase in testing is a realistic goal, which needs to be sup-
ported by the development of evidence-based guidelines and
health economic assessments to standardize testing, and focus
test resources equitably and effectively.
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